Puhlmann Markus, the Chief Medical Officer of Perspective Therapeutics, Inc., has made a notable acquisition of 41,000 shares of the company’s common stock. This transaction, which occurred over two days, is significant as it demonstrates the confidence of company leadership in the future prospects of the firm.

Background

Perspective Therapeutics, Inc. is a company engaged in the pharmaceutical preparations sector. The firm is listed under the Central Index Key (CIK) 0000728387. Its recent filings include a Form 4 submitted on November 13, 2026, which details the stock transactions made by its Chief Medical Officer. The company operates out of Seattle, Washington, and is incorporated in Delaware.

What the Filing Says

According to the recent SEC filing (accession number 0001193125-26-459395), Puhlmann acquired 6,000 shares on November 11, 2026, at a price of $0.83 per share. The following day, he purchased an additional 35,000 shares at a weighted average price of $0.8447. The filing notes that the shares were acquired in multiple transactions at prices ranging from $0.8408 to $0.8450.

Impact

This acquisition may affect various stakeholders, including investors and analysts watching Perspective Therapeutics. The increase in ownership by a key executive could signal positive expectations regarding the company’s direction and performance in the competitive pharmaceutical market.

What's Next

The filing does not say what happens next.